Citation sources

Updated weekly. Details via Crossref
Crossref Scopus Google Scholar
23 16 Search
2025
Disproportionality analysis of serotonin syndrome associated with selective serotonin reuptake inhibitors: a pharmacovigilance analysis
European Journal of Clinical Pharmacology
2025
Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Expert Opinion on Drug Safety
2025
Poisoning suicide due to paroxetine overdose toxicity aided by benzodiazepine and antipsychotic drugs
International Journal of Legal Medicine
2024
Pharmacogenetics in IBS: update and impact of GWAS studies in drug targets and metabolism
Expert Opinion on Drug Metabolism & Toxicology
2024
STRUCTURAL POLYMORPHISM OF CYP2D6 AND CYP2C19 GENES MODIFIES THE EFFICACY AND TOXICITY OF PHARMACOTHERAPY FOR DEPRESSIVE STATES
Bulletin of Problems Biology and Medicine
2024
Escitalopram-induced sinus bradycardia in coronary heart disease combined with depression: a case report and review of literature
Frontiers in Cardiovascular Medicine
2024
Pharmacokinetics and Pharmacodynamics: A Comprehensive Analysis of the Absorption, Distribution, Metabolism, and Excretion of Psychiatric Drugs
Pharmaceuticals
2024
The Influence of CYP2C19 Gene Polymorphism on Selective Serotonin Reuptake Inhibitors In Patients with Major Depressive Disorder: A Pharmacogenetic Prospecting Approach
Journal of Biomedicine and Translational Research
2023
CONTROL OF THE PHARMACOGENETICS OF ENZYMES’ MEDICINE BIOTRANSFORMATION – A TOOL FOR PROVIDING PERSONALIZED MEDICINE
Bulletin of Problems Biology and Medicine
2023
Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients
Frontiers in Genetics
2023
The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
Frontiers in Pharmacology
2022
Integrated Module of Multidimensional Omics for Peripheral Biomarkers (iMORE) in patients with major depressive disorder: rationale and design of a prospective multicentre cohort study
BMJ Open
2022
Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19
Frontiers in Pharmacology
2022
Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day
F1000Research
2022
Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day
F1000Research
2021
Fluoxetine pharmacokinetics and tissue distribution suggest a possible role in reducing SARS-CoV-2 titers
F1000Research
2021
Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease
Pharmaceuticals
2021
Therapy Response Prediction in Major Depressive Disorder: Current and Novel Genomic Markers Influencing Pharmacokinetics and Pharmacodynamics
Pharmacogenomics
2021
Head-to-Head Comparison of Sedation and Somnolence Among 37 Antipsychotics in Schizophrenia, Bipolar Disorder, Major Depression, Autism Spectrum Disorders, Delirium, and Repurposed in COVID-19, Infectious Diseases, and Oncology From the FAERS, 2004–2020
Frontiers in Pharmacology
2021
Lecture Notes in Bioengineering
2020
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
International Journal of Molecular Sciences
2020
Association of sleep among 30 antidepressants: a population-wide adverse drug reaction study, 2004–2019
PeerJ
Additional cited-by details will be shown when available from Crossref